多囊卵巢综合征患者内分泌代谢特征及其临床分析

目的分析多囊卵巢综合征(PCOS)患者的临床表现、内分泌特征及其临床危害,为PCOS患者的合理治疗及预防提供依据。方法我院内分泌门诊随机选择确诊为PCOS的患者80例,选择正常的妇女80例作为对照组,前瞻性观察并比较两组患者血清黄体生成素(LH)、雄激素(T)、胰岛素(INS)、雌二醇(E2)、催乳素(PRL)等的水平。采用口服葡萄糖耐量试验,抽血查血脂,评估糖代谢及胰岛素抵抗,对肥胖者和非肥胖者各个指标差异进行分析。结果PCOS组患者血清LH、T、INS、PRL水平明显>对照组(P<0.05),肥胖IR发生率(73.17%)明显>非肥胖IR的发生率(48.72%)、肥胖高INS血症发生率(36.59%)>非肥胖高胰岛素血症的发生率(20.51%)、糖耐量受损和糖尿病发生率为16.25%,5.00%、脂代谢异常表现为总胆固醇增高(6.25%),三酰甘油增高(12.50%)。结论PCOS患者存在LH、T、INS水平偏高、胰岛素抵抗状态,是导致患者各项临床症状的主要因素,肥胖在发病中起着重要作用,故临床合理用药降低这些实验指标水平、降低体质量指数、常规筛查各代谢指标、并对PCOS患者进行长期的监测和管理是临床治疗和防止远期并发症的关键。

The Endocrine Metabolic Characteristics and Clinical Analysis with Polycystic Ovary Syndrome Patients

Objective To analyze the clinical manifestations, endocrine features, and clinical hazards of the polycystic ovary syndrome (PCOS) patients, and so provide a reasonable basis for treatment and prevention to PCOS patients. Methods Selected 80 diagnosed cases of patients with PCOS from endocrine clinic in our hospital with randomly,and select 80 cases of normal women as control group, prospective study and compare the levels of serum luteinizing hormone (LH), androgen (T), insulin (INS), estradiol (E2), prolactin (PRL) in two groups. To assess the glucose metabolism and insulin resistance through the test of oral glucose tolerance and blood lipid investigation.to analysis the various indicators between obesity and non-obese. Results The levels of serum LH, T, INS, PRL in PCOS group were signifi cantly higher than the control group (P>0.05), the incidence of obesity IR (73.17%) was signifi cantly higherthan that of non-obese IR (48.72%), the incidence of hyperlipidemia (36.59%) of the obesity was higher than that of the non-obese (20.51%), the incidence rates of impaired glucose tolerance and diabetes were 16.25%, 5.00%, lipid metabolism varies usually higher total cholesterol (6.25% ), triglycerides increased (12.50%). Conclusions The higher levels of LH, T, INS and insulin resistance on the PCOS patients, that are the major factors leding to the clinical symptoms in patients. And obesity plays an important role in the pathogenesis too. So reduce the level of these experiments indicators through the clinical rational drug, lower body mass index, routine screening of the metabolic indicators, and long-term monitoring and management of pcos paitionts ,that are the key to treat and prevent the long-term complications clinical.